Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05207761
Other study ID # A71_05DDI2114
Secondary ID
Status Completed
Phase Phase 1
First received
Last updated
Start date January 19, 2022
Est. completion date November 2, 2022

Study information

Verified date January 2023
Source Chong Kun Dang Pharmaceutical
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study is a randomized, open-label, 2-period, parallel group, multiple-dose phase 1 study to evaluate drug-drug Interaction, safety and tolerability in case of the co-administration of D565 and D930, in healthy male subjects


Description:

To healthy male subjects of thirty-two (32), Investigational products are administered following treatments in each period


Recruitment information / eligibility

Status Completed
Enrollment 32
Est. completion date November 2, 2022
Est. primary completion date October 18, 2022
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Male
Age group 19 Years to 55 Years
Eligibility Inclusion Criteria: 1. Healthy adults volunteers aged between 19 and 55 years old at the time of screening 2. Weight = 55 kg, Calculated Body Mass Index(BMI) of 18.0 to 30.0 kg/m2 * BMI = Weight(kg)/ Height(m)2 3. Individuals who sign an informed consent form and decide to participate in the study after being fully informed of the study prior to participation 4. Individuals who are suitable as a subject for this study at the discretion of the researcher as a result of screening tests such as examination, laboratory tests and questionnaires Exclusion Criteria: 1. Individuals who have other clinically significant cardiovascular system, respiratory system, liver, renal, nervous system, endocrine system, blood-oncology, psychiatric disorders, urinary system or ophthalmic diseases or have a history 2. Individuals who satisfy the following items during the interview or examination - Individuals with a history of or sign or symptoms of a disease of the visual system - Individuals who had an ophthalmic surgery including for refractive correction surgery such as LASIK. - Individuals with corrected visual acuity of 20/40 or less - Individuals who have experienced side effects after wearing contact lenses or who have worn contact lenses within the last month - Individuals who have more than 21mmHg or less than 10mmHg on either side of the intraocular pressure test - Individuals who show abnormal findings in other ophthalmic examinations 3. Individuals who have a history of hypersensitivity to the active ingredient and component of the investigational drug, or to the drug in the same class as the active ingredient 4. Individuals with sitting systolic blood pressure = 140 mmHg or = 80 mmHg or sitting diastolic blood pressure = 90 mmHg or = 45 mmHg 5. Individuals with the following results at screening test - AST, ALT, ?-GT > 2x the upper limit of the normal range - Total bilirubin > 2.0 mg/dL - eGFR(CKD-EPI) < 60 mL/min/1.73m2 6. Individuals who continue to drink(over 21 units/week) within 1 month or cannot abstain from alcohol during the clinical trial period 7. Individuals who tested positive in an alcohol breath analysis 8. Individuals who continuously smoke within one month(including e-cigarettes, over 10 fees/day) or who cannot quit smoking during the clinical trial period; 9. Individuals who cannot restrict the intake of grapefruit or grapefruit-containing food from 3 days before administration of investigational drugs to the final pharmacokinetic blood sample collection 10. Individuals who tested positive for urine cotinine at screening test 11. Individuals who took ethical(ETC) or oriental medicine within 2 weeks or over the counter(OTC) within 1 week before the expected first dose 12. Individuals taking medication known to significantly induce or inhibit drug metabolizing enzymes within 1 month before the expected first dose 13. Individuals with a medical history of significant drug abuse or positive for abuse drug in urine test results at screening 14. Individuals who had been administered investigational product(s) of other clinical study within the 6 months prior to the first dose of this study 15. Individuals who donated whole blood within the 2 months, or donated blood components within 1 month, or received a blood transfusion with 1month prior to the first dose or plan to donate blood or transfusion during the clinical trial period 16. Individuals who are unable to use an appropriate medically approved method of contraception for themselves, their spouses, or partners during the entire clinical trial period and for at least 90 days after the last investigational drug administration and cannot donate sperm during this period 17. Individuals who were deemed to be inappropriate to participate in the study by the investigator

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
D565
Q.D. in both eye
D930
T.I.D in both eye

Locations

Country Name City State
Korea, Republic of Seoul National University College of Medicine and Hospital Seoul

Sponsors (1)

Lead Sponsor Collaborator
Chong Kun Dang Pharmaceutical

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type Measure Description Time frame Safety issue
Primary AUCtau,ss of D565(Sequence1) Area under the D565 concentration in blood-time curve from 0 to t at steady state 1day 0hour ~ 99day 0hour
Primary AUCtau,ss of D930(Sequence1) Area under the D930 concentration in blood-time curve from 0 to t at steady 8day 0hour ~ 99day 0hour
Primary AUCtau,ss of D565(Sequence2) Area under the D565 concentration in blood-time curve from 0 to t at steady state 96day 0hour ~ 99day 0hour
Primary AUCtau,ss of D930(Sequence2) Area under the D930 concentration in blood-time curve from 0 to t at steady 1day 0hour ~ 99day 0hour
Primary Cmax,ss of D565(Sequence1) The maximum D565 concentration between 0 and t at steady state 1day 0hour ~ 99day 0hour
Primary Cmax,ss of D930(Sequence1) The maximum D930 concentration between 0 and t at steady state 8day 0hour ~ 99day 0hour
Primary Cmax,ss of D565(Sequence2) The maximum D565 concentration between 0 and t at steady state 96day 0hour ~ 99day 0hour
Primary Cmax,ss of D930(Sequence2) The maximum D930 concentration between 0 and t at steady state 1day 0hour ~ 99day 0hour
See also
  Status Clinical Trial Phase
Recruiting NCT06000865 - Glaucoma Rehabilitation With Action viDeo Games and Exercise - GRADE N/A
Recruiting NCT06278597 - Automatic Evaluation of the Anterior Chamber Angle Width by a New Non-contact Optical Device N/A
Active, not recruiting NCT04271709 - Manhattan Vision Screening and Follow-Up Study (NYC-SIGHT) N/A
Recruiting NCT03274024 - The Asia Primary Tube Versus Trab (TVT) Study N/A
Completed NCT04552964 - Assessment of the Impact of an add-on and Its Smartphone Application on the Daily Management of Glaucoma N/A
Recruiting NCT01957267 - Functional and Structural Imaging for Glaucoma
Active, not recruiting NCT04624698 - iStent Inject New Enrollment Post-Approval Study N/A
Completed NCT04020705 - The Efficacy of Citicoline in Eyedrops (OMK1) in Reducing the Progression of Glaucoma N/A
Completed NCT03150160 - Additive Effect of Twice-daily Brinzolamide 1%/Brimonidine 0.2%Combination as an Adjunctive Therapy to Travoprost in Patients With Normal Tension Glaucoma Phase 4
Not yet recruiting NCT05581498 - Glaucoma Exercise as Medicine Study (GEMS). N/A
Recruiting NCT02921568 - Side-by-Side Comparison of P200TE and Spectral OCT/SLO on Diseased Eyes N/A
Active, not recruiting NCT02901730 - Clinical Study of LPI With Different Laser Wavelengths N/A
Completed NCT02955849 - A Trial of China Laser and Surgery Study Glaucoma in Rural China Early Phase 1
Recruiting NCT02471105 - Investigation of IOP and Tolerability of Bimatoprost 0.01% and Tafluprost Unit Dose Preservative Free 15 Microgram/ml Phase 4
Recruiting NCT02554214 - Pilot Clinical Trial on a New Adjustable Glaucoma Drainage Device N/A
Active, not recruiting NCT02390284 - Stop Retinal Ganglion Cell Dysfunction Study Phase 3
Completed NCT02520674 - Glaucoma Screening With Smartphone Ophthalmology N/A
Completed NCT02628223 - 180 Degree vs. 360 Degree Selective Laser Trabeculoplasty as Initial Therapy for Glaucoma N/A
Completed NCT02653963 - Triamcinolone for Ahmed Glaucoma Valve N/A
Completed NCT02390245 - Philadelphia Telemedicine Glaucoma Detection and Follow-Up Study N/A